Subcutaneous efalizumab is not effective in the treatment of alopecia areata

Vera H. Price, Maria K Hordinsky, Elise A. Olsen, Janet L. Roberts, Elaine C. Siegfried, Elyse S. Rafal, Neil J. Korman, Basel Altrabulsi, Hoi M. Leung, Marvin R. Garovoy, Ivor Caro, David A. Whiting

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Background: Alopecia areata (AA) is a T-cell-mediated autoimmune disease. Efalizumab is a T-cell-targeted therapy approved for the treatment of psoriasis. Objective: To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA. Methods: Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The trial consisted of three 12-week periods-a double-blind treatment period, an open-label efalizumab treatment period, and a safety follow-up. Results: There were no statistical differences between treatment groups in percent hair regrowth, quality-of-life measures, or changes in biologic markers of disease severity after 12 or 24 weeks. In both groups, there was an approximately 8% response rate for hair regrowth (at 12 weeks). Efalizumab was well tolerated. Limitations: Numbers were too small for certain analyses. Conclusion: A 3- to 6-month trial of efalizumab was not effective in promoting hair regrowth in this small cohort of patients with moderate-to-severe AA.

Original languageEnglish (US)
Pages (from-to)395-402
Number of pages8
JournalJournal of the American Academy of Dermatology
Issue number3
StatePublished - Mar 2008

Bibliographical note

Funding Information:
Supported by Genentech, Inc.


Dive into the research topics of 'Subcutaneous efalizumab is not effective in the treatment of alopecia areata'. Together they form a unique fingerprint.

Cite this